PhoreMost and ThinkCyte have entered a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI).
The partnership leverages both companies’ technologies in high-throughput drug discovery, PhoreMost’s phenotypic screening platform, SITESEEKER, and ThinkCyte’s AI-driven cell characterisation and sorting platform, Ghost Cytometry.
Driven by advances in cell-based phenotypic screening tools and novel target discovery technologies, phenotypic drug discovery (PDD) can find completely new drug targets and disease mechanisms.
By combining SITESEEKER to identify novel druggable targets with Ghost Cytometry to identify subtle phenotypic changes in living cells, the partnership aims to develop a new approach to high-content phenotypic screening.
Dr Benedict Cross, CTO of PhoreMost, said: “By combining ThinkCyte’s AI-based platform to detect novel, disease-related phenotypes with our SITESEEKER phenotypic screening platform, we hope to more efficiently uncover a broad range of novel targets and translate them into high-quality first-in-class therapeutic assets.”
Waichiro Katsuda, CEO at ThinkCyte, added: “We look forward to working together with PhoreMost to advance our technologies towards the shared goal of making meaningful impact for people suffering from serious diseases.”